Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies with dismal 5-year survival rates. Characterized by its complex tumor microenvironment and resistance to conventional therapies, PDAC has historically been difficult to treat effectively. Recent advances in molecular profiling have revolutionized our understanding of the genetic landscape of pancreatic cancer. This review examines how molecular genetics is driving precision medicine approaches in pancreatic cancer, with particular focus on KRAS-targeted therapies. Understanding these developments is crucial for clinicians seeking to optimize treatment strategies and improve outcomes for patients with pancreatic cancer.